Skip navigation

Neurological products and therapies news

Latest news from Renishaw in the neurosurgical field

Latest articles

  • Renishaw’s neurolocate 2D module makes frameless robotic neurosurgery more accessible

    neurolocate with laser tool holder A new frameless patient registration module for the neuromate® surgical robot, the neurolocate™ 2D module, has obtained a CE mark. Global engineering company Renishaw will now offer the neurolocate 2D module to hospitals across Europe to help save time and costs by realising the benefits of intraoperative imaging.

  • Renishaw demonstrates functional stereotactic neurosurgery expertise at ESSFN

    Renishaw neuromate robot with neurolocate module At the 23rd congress of the European Society for Stereotactic and Functional Neurosurgery (ESSFN), global engineering company Renishaw will present its range of products for stereotactic neurosurgery. Held in Edinburgh, Scotland from September 26th to 29th, 2018, the event brings together neuroscientists, neurosurgeons and psychiatrists to discuss the latest advances in the field.

  • Renishaw showcases neuro-oncology solutions at ISPNO

    Drug_delivery Renishaw, a global engineering company with expertise in healthcare, is exhibiting at the International Symposium on Paediatric Neuro-Oncology (ISPNO) 2018. From June 30th to July 3rd at the Hyatt Regency Hotel in Denver, Colorado, USA the company will showcase its neurological products which improve accuracy and reduce procedure time in neurosurgery.

  • Renishaw exhibits at Canadian Neurological Sciences Federation Congress

    neuromate: SEEG From June 24th to June 27th, 2018, global engineering technologies company Renishaw will attend the Canadian Neurological Sciences Federation’s annual congress. The event, held at the Halifax Convention Centre, Nova Scotia, provides multidisciplinary courses relevant to all neuroscience specialities. On booth 304, Renishaw will showcase its neuromate® stereotactic robot and neuroinspire™ its surgical planning software.

  • Renishaw's integrated neurosurgery solution cleared for sale in USA

    Healthcare centre of excellence OR The Food and Drug Administration (FDA) has recently cleared the use of Renishaw’s neuromate® Gen III surgical robot with the neuroinspire™ surgical planning software in the USA. Both were previously cleared for use separately, but not in combination ─ This latest clearance means that neurosurgeons across America will now be able to deliver surgical plans created using neuroinspire software directly using the neuromate surgical robot, helping to improve patient outcomes.

All articles